Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16189
Title: A conceptualization of the utility of subjective cognitive decline in clinical trials of preclinical Alzheimer's disease
Austin Authors: Buckley, Rachel F;Villemagne, Victor L ;Masters, Colin L ;Ellis, Kathryn A;Rowe, Christopher C ;Johnson, Keith;Sperling, Reisa;Amariglio, Rebecca
Affiliation: Austin Health, Heidelberg, Victoria, Australia
Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Victoria, Australia
Melbourne School of Psychological Sciences, University of Melbourne, Melbourne, Australia
Centre for Alzheimer Research and Treatment, Department of Neurology, Brigham Women's Hospital/Harvard Medical School, Boston, MA, USA
Athinoula A. Martinos Center for Biomedical Imaging, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
The Academic Unit for Psychiatry of Old Age, Department of Psychiatry, University of Melbourne, Melbourne, Victoria, Australia
Department of Neurology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA
Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA
Issue Date: 11-Aug-2016
metadata.dc.date: 2016-08-11
Publication information: Journal of Molecular Neuroscience 2016; online first: 11 August
Abstract: This commentary outlines a conceptual model for subjective cognitive decline (SCD) in relation to Alzheimer's disease (AD) biomarkers in the preclinical stages of disease and a framework for effectively utilizing SCD in secondary prevention clinical trials. Mounting evidence supports the notion that SCD is sensitive to encroaching Aβ-amyloid and neurodegeneration. SCD has also been shown to provide additive information of AD-dementia risk beyond what is known about the biomarker status of the individual. Thus, we provide recommendations for the implementing SCD measurement in clinical trials. We argue that SCD can be measured at three catch points within the course of the clinical trial: firstly, at the initial recruitment and screening phase; secondly, to create more robust estimates of rates of AD-dementia progression; and finally, to measure subjective experiences of cognitive change and quality of life over the course of the trial as a proxy of clinically meaningful functional improvement. We provide recommendations of how SCD can be approached at each of these points. SCD is an important component of the preclinical AD-dementia trajectory. Future studies need to elucidate the interactive influence of Aβ-amyloid and tau on SCD from a spatiotemporal perspective. Even as this evidence accrues, it is clear that SCD can provide unique and additive information about rates of progression and subjectively experienced cognitive change within clinical trials.
URI: http://ahro.austin.org.au/austinjspui/handle/1/16189
DOI: 10.1007/s12031-016-0810-z
ORCID: 0000-0002-5356-5537
0000-0003-3910-2453
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/27514526
Type: Journal Article
Subjects: Alzheimer’s disease
Amyloid
Cognition
Preclinical
Subjective cognitive decline
Tau
Appears in Collections:Journal articles

Show full item record

Page view(s)

6
checked on Dec 6, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.